Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer

Laboratory Investigation

Volumn 79, Issue 7, 1999, Pages 869-877

  Sharp, Julie A ^a   Sung, Victoria ^b   Slavin, John ^d   Thompson, Erik W ^a,b,c   Henderson, Michael A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b GEORGETOWN UNIVERSITY   (United States)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; GLYCINE; INTEGRIN; MESSENGER RNA; OSTEOPONTIN; SIALOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BONE AND BONES; BREAST NEOPLASMS; CONSERVED SEQUENCE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, NUDE; OSTEOPONTIN; RATS; RNA, MESSENGER; SIALOGLYCOPROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032764717     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bautista DS, Xuan JW, Hota C, Chambers AF, and Harris JF (1994). Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 269:23280-23285.
2. Bellahcene A, Merville M-P, and Castronovo V (1994). Expression of bone sialoprotein, a bone matrix protein in human breast cancer. Cancer Res 54:2823-2826.
3. Bellahcene A, Kroll M, Liebens F, and Castronovo V (1996a). Bone sialoprotein expression in primary human breast cancer is associated with bone metastasis development. J Bone Miner Res 11:665-670.
4. Bellahcene A, Menard S, Bufalino R, Moreau L, and Castronovo V (1996b). Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353.
5. Bellahcene A and Castronovo V (1997). Expression of bone matrix proteins in human breast cancer: Potential roles in microcalcification formation and in the genesis of bone metastases. Bull Cancer 84:17-24.
6. Bellahcene A, Maloujahmoum N, Fisher LW, Pastorino H, Tagliabue E, Menard S, and Castronovo V (1997). Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183-188.
7. Bianco P, Fisher LW, Young MF, Termine JD, and Robey PG (1991). Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int 49:421-426.
8. Brown LF, Papadopoulod-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF, and Senger DR (1994). Osteopontin expression and distribution in human carcinomas. Am J Pathol 145:610-623.
9. Chellaiah M, Fitzgerald C, Filardo EJ, Cheresh DA, and Hruska KA (1996). Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin alpha v-subunit. Endocrinology 137:2432-2440.
10. Crawford HC, Matrisian LM, and Liaw L (1998). Distinct roles of osteopontin in host activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58:5206-5212.
11. Davies J, Warwick J, Totty N, Philip R, Helrich M, and Horton M (1989). The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 109:1817-1826.
12. Ek-Rylander B, Flores M, Wendel M, Heinegard D, and Andersson G (1994). Dephosphorylation of osteopontin and bone sialoprotein by osteoclastic tartrate-resistant acid phosphatase: Modulation of osteoclast adhesion in vitro. J Biol Chem 269:14853-14856.
13. Faccio R, Grano M, Colucci S, Zallone AZ, Quaranta V, and Pelletier AJ (1998). Activation of alphav beta3 integrin on human osteoclast-like cells stimulates adhesion and migration in response to osteopontin. Biochem Biophys Res Commun 249:522-525.
14. Fisher LW, Whitson SW, Avioli LV, and Termine JD (1983). Matrix sialoprotein of developing bone. J Biol Chem 258: 12723-12727.
15. Fisher LW, Stubbs JT III, and Young MF (1995). Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. Acta Orthop Scand 266(Suppl):61-65.
16. Gillespie MT, Thomas RJ, Pu Z-Y, Zhou H, Martin TJ, and Findlay DM (1997). Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers, Int J Cancer 73:812-815.
17. Helfrich MH, Nesbitt SA, Dorey EL, and Norton MA (1992). Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res 7:335-343.
18. Hirota S, Ito A, Nagoshi J, Takeda M, Kurata A, Takatsuka Y, Kohri K, Nomura S, and Kitamura Y (1995). Expression of bone matrix protein messenger ribonucleic acids in human breast cancers: Possible involvement of osteopontin in development of calcifying foci. Lab Invest 72:64-69.
19. Hunter GK and Goldberg HA (1993). Nucleation of hydroxyapatite by bone sialoprotein. Proc Natl Acad Sci U S A 90:8562-8565.
20. Hunter GK, Hauschka PV, Poole AR, Rosenberg LC, and Goldberg HA (1996). Nucleation and inhibition of hydroxyapatite formation by mineralized tissue proteins. Biochem J 317:59-64.
21. Ibaraki K, Termine JD, Whitson SW, and Young MF (1992). Bone matrix mRNA expression in differentiating foetal bovine osteoblasts. J Bone Miner Res 7:743-753.
22. Kasugai S, Todescan R Jr, Nagata T, Yao KL, Butler WT, and Sodek J (1991). Expression of bone matrix proteins associated with mineralized tissue formation by adult rat bone marrow cells in vitro: Inductive effects of dexamethasone on the osteoblastic phenotype. J Cell Physiol 147:111-120.
23. Loeser RF (1993). Integrin-mediated attachment of articular chondrocytes to extracellular matrix proteins. Arthritis Rheum 36:1103-1110.
24. Lopez CA, Hoyer JR, Wilson PD, Waterhouse P, and Denhardt DT (1993). Heterogeneity of osteopontin expression among nephrons in mouse kidneys and enhanced expression in sclerotic glomeruli. Lab Invest 69:355-363.
25. Mintz KP, Grzesik WJ, Midura RJ, Robey PG, Termine JD, and Fisher LW (1993). Purification and fragmentation of nondenatured bone sialoprotein: Evidence for a cryptic, RGD-resistant cell attachment domain. J Bone Miner Res 8:985-995.
26. Oates AJ, Barraclough R, and Rudland PS (1996). The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97-104.
27. Oates AJ, Barraclough R, and Rudland PS (1997). The role of osteopontin in tumourigenesis and metastasis. Invasion Metastasis 17:1-15.
28. Oldberg A, Franzen A, Heinegard D, Pierschbacher M, and Ruoslahti E (1988). Identification of a bone sialoprotein receptor in osteosarcoma cells. J Biol Chem 263:19433-19436.
29. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, Mintz KA, Robey PG, Teitelbaum SL, and Cheresh DA (1993). Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem 268:9901-9907.
30. Sambrook J, Fritsch EF, and Maniatis T (1989). Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor, New York, Laboratory Press.
31. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, Armbruster FP, and Ziegler R (1996). Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 81:3289-3294.
32. Senger DR, Perruzzi CA, and Papadopoulos A (1989). Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299.
33. Sodek J, Chen J, Nagata T, Kasugai S, Todescan R Jr, Li IW, and Kim RH (1995). Regulation of osteopontin expression in osteoblasts. Ann N Y Acad Sci 760:223-241.
34. Somerman MJ, Fisher LW, Foster RA, and Sauk JJ (1988). Human bone sialoprotein I and II enhance fibroblast attachment in vitro. Calcif Tissue Int 43:50-53.
35. Stubbs III JT, Mintz KP, Eanes ED, Torchia DA, and Fisher, LW (1997). Characterization of native and recombinant bone sialoprotein delineation of the mineral -binding and cell adhesion domains and structural analysis of the RGD domain. J Bone Miner Res 12:1210-1222.
36. Sung V, Gilles C, Murray A, Clarke R, Aaron AD, Azumi N, and Thompson EW (1998a). The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. Exp Cell Res 241:273-284.
37. Sung V, Stubbs JT III, Fisher L, Aaron AD, and Thompson EW (1998b). Bone sialoprotein supports breast cancer cell adhesion, proliferation and migration through the differential usage of the αvβ3 and αvβ5 integrins. J Cell Physiol 176:482-494.
38. Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME, Martin GR, and Dickson RB (1992). Association of increased basement membrane-invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J Cell Physiol 150:534-544.
39. Thompson EW, Brunner N, Torri J, Johnson MD, Boulay V, Wright A, Lippman ME, Steeg PS, and Clarke R (1993). The invasive and metastatic properties of hormone-independent but hormone-responsive variants of MCF-7 human breast cancer cells. Clin Exp Metastasis 11:15-26.
40. Thompson EW, Sung V, Lavigne M, Baumann K, Aaron AD, Azumi N, and Clarke R (In press, 1999). LCC15-MB: A human breast cancer cell line from a femoral bone metastasis. Clin Exp Metastasis.
41. Tuck AB, O'Malley FP, Singhal H, Tonkin KS, Harris JF, Bautista D, and Chambers AF (1997). Osteopontin and p53 expression are associated with tumour progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med 121:578-584.
42. van der Pluijim G, Vloedgraven HJM, Ivanov B, Robey FA, Grzesik WJ, Robey PG, Papapoulos SE, and Lowik CWGM (1996). Bone Sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res 56:1948-1955.
43. van Dijk S, D'Errico JA, Somerman MJ, Farach-Carson MC, and Butler WT (1993). Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment. J Bone Miner Res 8:1499-1506.
44. Waltregny D, Bellahcene A, Van Riet I, Fisher LW, Young M, Fernandez P, Dewe W, de Levai J, and Castronovo V (1998). Prognostic value of bone Sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90: 1000-1008.
45. Withold W, Armbruster FP, Karmatschek M, and Reinauer H (1997). Bone Sialoprotein in serum of patients with malignant bone diseases. Clin Chem 43:85-91.
46. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, and Chambers AF (1995). Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 57:680-690.
47. Zhou H, Choong P, McCarthy R, Chou ST, Martin TJ, and Ng KW (1994). In situ hybridisation to show sequential expression of osteoblast gene markers during bone formation in ivo. J Bone Miner Res 9:1489-1499.